Literature DB >> 20007626

New opportunities for the management and therapy of hepatitis C in correctional settings.

C Kent Martin1, Jeffrey E Hostetter, John J Hagan.   

Abstract

Hepatitis C in prison populations is now a major public health problem, and large numbers of correctional facilities have no comprehensive management program, often because of formidable projected costs and tightening budget constraints. The North Dakota Department of Corrections and Rehabilitation has operated a management and therapy program since 2002 using consensus interferon and ribavirin with 45% cost savings. The program has provided excellent sustained viral responses: 54.2% for genotype 1 hepatitis C, 75% for genotypes 2 and 3, and 63.6% overall.

Mesh:

Substances:

Year:  2010        PMID: 20007626      PMCID: PMC2791263          DOI: 10.2105/AJPH.2008.147629

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  19 in total

1.  A randomized trial of consensus interferon in combination with ribavirin as initial treatment for chronic hepatitis C.

Authors:  Giovanna Fattovich; Irene Zagni; Eliseo Minola; Martina Felder; Pierangelo Rovere; Antonio Carlotto; Sergio Suppressa; Anna Miracolo; Claudio Paternoster; Caterina Rizzo; Angelo Rossini; Paolo Benedetti; Marco Capanni; Chiara Ferrara; Paolo Costa; Tosca Bertin; Maurizio Pantalena; Lorenzo Lomonaco; Chiara Scattolini; Giuseppe Mazzella; Massimo Giusti; Sergio Boccia; Stefano Milani; Renato Marin; Maria Lisa Ribero; Alessandro Tagger
Journal:  J Hepatol       Date:  2003-11       Impact factor: 25.083

Review 2.  HIV/AIDS and other infectious diseases among correctional inmates: transmission, burden, and an appropriate response.

Authors:  Theodore M Hammett
Journal:  Am J Public Health       Date:  2006-01-31       Impact factor: 9.308

3.  The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.

Authors:  M J Alter; D Kruszon-Moran; O V Nainan; G M McQuillan; F Gao; L A Moyer; R A Kaslow; H S Margolis
Journal:  N Engl J Med       Date:  1999-08-19       Impact factor: 91.245

4.  Feasibility and outcome of HCV treatment in a Canadian federal prison population.

Authors:  John Farley; Shawn Vasdev; Benedikt Fischer; Emma Haydon; Jürgen Rehm; Theresa A Farley
Journal:  Am J Public Health       Date:  2005-08-30       Impact factor: 9.308

5.  Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy.

Authors:  Richard A Del Rio; Anthony B Post; Mendel E Singer
Journal:  Hepatology       Date:  2006-12       Impact factor: 17.425

6.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

7.  The role of consensus interferon in the current treatment of chronic hepatitis C viral infection.

Authors:  Eleanor N Fish; Stephen A Harrison; Tarek Hassanein
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-09

8.  Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

Authors:  Gary L Davis; John B Wong; John G McHutchison; Michael P Manns; Joann Harvey; Janice Albrecht
Journal:  Hepatology       Date:  2003-09       Impact factor: 17.425

9.  Treatment of chronic hepatitis C in a state correctional facility.

Authors:  Scott A Allen; Anne C Spaulding; Albert M Osei; Lynn E Taylor; Asya M Cabral; Josiah D Rich
Journal:  Ann Intern Med       Date:  2003-02-04       Impact factor: 25.391

Review 10.  Treating hepatitis C in the prison population is cost-saving.

Authors:  Jennifer A Tan; Tom A Joseph; Sammy Saab
Journal:  Hepatology       Date:  2008-11       Impact factor: 17.425

View more
  8 in total

1.  Survey of US Correctional Institutions for Routine HCV Testing.

Authors:  Curt G Beckwith; Ann E Kurth; Lauri Bazerman; Liza Solomon; Emily Patry; Josiah D Rich; Irene Kuo
Journal:  Am J Public Health       Date:  2015-01       Impact factor: 9.308

2.  An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver.

Authors:  Robert P Myers; Alnoor Ramji; Marc Bilodeau; Stephen Wong; Jordan J Feld
Journal:  Can J Gastroenterol       Date:  2012-06       Impact factor: 3.522

3.  A Budget Impact Analysis of Newly Available Hepatitis C Therapeutics and the Financial Burden on a State Correctional System.

Authors:  John T Nguyen; Josiah D Rich; Bradley W Brockmann; Fred Vohr; Anne Spaulding; Brian T Montague
Journal:  J Urban Health       Date:  2015-08       Impact factor: 3.671

4.  Lack of health insurance limits the benefits of hepatitis C virus screening: insights from the National Health and Nutrition Examination Hepatitis C follow-up study.

Authors:  Ivo Ditah; Badr Al Bawardy; Humberto C Gonzalez; Behnam Saberi; Callistus Ditah; Patrick S Kamath; Michael Charlton
Journal:  Am J Gastroenterol       Date:  2015-03-10       Impact factor: 10.864

Review 5.  Public health and the epidemic of incarceration.

Authors:  Dora M Dumont; Brad Brockmann; Samuel Dickman; Nicole Alexander; Josiah D Rich
Journal:  Annu Rev Public Health       Date:  2012-01-03       Impact factor: 21.981

6.  "Seek, test, treat and retain" for hepatitis C in the United States criminal justice system.

Authors:  Sarah Larney; Curt G Beckwith; Nickolas D Zaller; Brian T Montague; Josiah Rich
Journal:  Int J Prison Health       Date:  2014

Review 7.  Hepatitis C virus infection and prisoners: Epidemiology, outcome and treatment.

Authors:  Rosa Zampino; Nicola Coppola; Caterina Sagnelli; Giovanni Di Caprio; Evangelista Sagnelli
Journal:  World J Hepatol       Date:  2015-09-28

Review 8.  Hepatitis C in European prisons: a call for an evidence-informed response.

Authors:  Amber Arain; Geert Robaeys; Heino Stöver
Journal:  BMC Infect Dis       Date:  2014-09-19       Impact factor: 3.090

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.